[Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases].
OBJECTIVE
To describe the complete responses in our patients with metastatic renal cancer treated with tyrosine kinase inhibitors.


METHODS
Between June 2007 and December 2014 we treated in our department 43 patients with metastatic renal cancer with antiangiogenic drugs.


RESULTS
9.3% (4/43) of the patients treated with antiangiogenic drugs obtained complete response according to RECIST 1.1 criteria. In 3 of the 4 patients, complete response was obtained during the first-line treatment with sunitinib at doses of 50 mgr/day in a 4/2 scheme and the remaining patient obtained it with second line axitinib at doses of 10 mgr/day.


CONCLUSIONS
Tyrosine kinase inhibitors can induce complete responses in patients with metastatic renal cancer. Discontinuation of treatment with tyrosine kinase inhibitors after a complete response may be an option.
Hospital de Jerez de La Frontera. Jerez de La Frontera. Cádiz. España.
M
M
Soto
Hospital de Jerez de La Frontera. Jerez de La Frontera. Cádiz. España.
R
R
Campanario
Hospital de Jerez de La Frontera. Jerez de La Frontera. Cádiz. España.
R
R
Saiz
Hospital de Jerez de La Frontera. Jerez de La Frontera. Cádiz. España.
A
A
Juárez
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007191:Indazoles / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011758:Pyrroles / Q000627:therapeutic use*; D012074:Remission Induction; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007093:Imidazoles; D007191:Indazoles; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D000077784:Axitinib; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib